Hints and tips:
Related Special Reports
...In 1995, the trust divested itself of any interest in pharmaceuticals by selling all remaining stock to Glaxo plc....
...Peltz had built a stake in the early months of 2022, after Unilever’s share price slumped following its botched attempt to buy GlaxoSmithKline’s consumer healthcare arm, later spun out as Haleon....
...GlaxoSmithKline: shingle minded Worried about shingles? GlaxoSmithKline is....
...GlaxoSmithKline will apply for approval for its respiratory syncytial virus vaccine for older adults, after reporting data showing the shot is the first to work in the vulnerable age group for the major...
...GlaxoSmithKline’s chief executive said a shareholder vote in favour of spinning off its consumer healthcare business vindicated the UK drugmaker’s decision to turn down a £50bn takeover offer from Unilever...
...GlaxoSmithKline has reached an agreement to buy blood cancer specialist Sierra Oncology for £1.5bn as part of plans to strengthen its drug pipeline after pressure from activist investors....
...GlaxoSmithKline chief executive Emma Walmsley said the imminent spin-off of the consumer health division Haleon would untangle the UK drugmaker’s complex “Gordian knot” structure and enable her to tackle...
...Now, pharmaceutical companies including Sanofi and GlaxoSmithKline, as well as the Covid mRNA vaccine makers, are trialling other shots, such as annual influenza vaccines, using the technology....
...The merged word reflects GlaxoSmithKline’s optimism about its soon-to-be demerged consumer business....
...Sanofi and GlaxoSmithKline have reported promising results from trials of their Covid-19 vaccine, which has proved to be particularly effective against the Omicron strain of coronavirus....
...Sanofi and GlaxoSmithKline’s next generation Covid-19 vaccine could be used as a booster, after new data suggested that it elicited a strong immune response against the Omicron variant....
...Unilever expects the strongest cost inflation in decades to hit profitability for two years, adding to pressure on chief executive Alan Jope, who ruled out large acquisitions after a failed bid for GlaxoSmithKline...
...GlaxoSmithKline is buying Boston-based biotech Affinivax in a transaction worth up to $3.3bn, bolstering its vaccines business with new technology....
...GlaxoSmithKline’s ViiV Healthcare is “actively negotiating” a voluntary licence on the patents for its injectable HIV prevention drug to make it more widely available in poorer nations, where fewer than...
...Pfizer will sell down its stake in Haleon, its consumer health joint venture with GlaxoSmithKline, after a London listing planned for July 18....
...Trian Fund Management founder has heightened expectations of a drastic overhaul at Unilever, which faces discontent among its broader investor base over lacklustre performance and a failed attempt to buy GlaxoSmithKline...
...The latest price increases follow a turbulent period for Unilever in which it made three bids for the consumer health division of GlaxoSmithKline late last year, only to face anger from shareholders when...
...A question at GlaxoSmithKline’s 2019 AGM asked how long “we have to put up with” chief executive Emma Walmsley, while noting then-chair Philip Hampton’s focus on “trying to persuade other companies to employ...
...Bluebell Capital Partners has called for the resignation of the GlaxoSmithKline chair, as the activist investor pushes for change at the top of the UK drugmaker....
...Bumper sales of GlaxoSmithKline’s Covid-19 antibody treatment and a bounce back in demand for its shingles vaccine helped the UK drugmaker beat expectations in the first quarter....
...Several hundred GlaxoSmithKline workers have voted to go on strike after rejecting a below inflation pay rise, setting the stage for an industrial battle unusual in the pharmaceutical industry....
...*This article has been amended to remove an incorrect forecast for GlaxoSmithKline’s consumer health business....
...The odds, like shareholders, are stacked against Unilever’s £50bn bid for GlaxoSmithKline’s consumer health unit. But if it wins over the doubters at a higher price, assets will go on the block....
...And activists aren’t the only ones upending UK plc. Private equity groups have been snatching up British companies at a record pace....
...Shareholder discontent hit a high note at the conglomerate earlier this year following news of Unilever’s three failed approaches to buy UK drugmaker GlaxoSmithKline’s consumer health business, landing its...
International Edition